Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue
Product revenue	$ 17,976	$ 12,595	$ 37,367	$ 28,336
Service revenue	13,446	6,915	27,177	13,396
Research and development contract revenue	10	371	313	1,045
Total revenue	31,432	19,881	64,857	42,777
Cost of product revenue	15,145	11,058	30,636	24,951
Cost of service revenue	16,201	9,217	34,322	19,143
Cost of research and development contract revenue	10	699	372	1,887
Research and development expense	4,131	1,644	10,457	4,295
Legal reserve		2,400		2,400
Selling, general and administrative expenses	8,201	5,559	23,952	14,817
Operating loss	(12,256)	(10,696)	(34,882)	(24,716)
Interest and other income	28	628	91	722
(Loss) gain on acquisition activity, net	(116)		(116)	1,014
Change in fair value of common stock warrant liability	2,167	485	4,603	(58,371)
Interest and other expense	(36)	(93)	(186)	(305)
Loss before income taxes	(10,213)	(9,676)	(30,490)	(81,656)
Income tax benefit		325		325
Net loss attributable to the Company	(10,213)	(9,351)	(30,490)	(81,331)
Preferred stock dividends declared	(25)	(26)	(78)	(130)
Net loss attributable to common shareholders	$ (10,238)	$ (9,377)	$ (30,568)	$ (81,461)
Net loss per share:
Basic and diluted (in dollars per share)	$ (0.06)	$ (0.06)	$ (0.17)	$ (0.53)
Weighted average number of common shares outstanding	177,369,017	169,557,223	174,724,746	154,539,225
Basic weighted average number of common shares outstanding	177,369,017	169,557,223	174,724,746	154,539,225